WHO consolidated guidelines on tuberculosis

Module 3: Diagnosis

Tests for tuberculosis infection

World Health Organization

WHO consolidated guidelines on tuberculosis

Module 3: Diagnosis

Tests for tuberculosis infection

World Health Organization

WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection

ISBN 978-92-4-005608-4 (electronic version)

ISBN 978-92-4-005609-1 (print version)

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (http://www.wipo.int/amc/en/mediation/rules/).

Suggested citation. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis. Tests for tuberculosis infection. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see https://www.who.int/copyright.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design by Inís Communication

Contents

Acknowledgements v

Abbreviations and acronyms x

Executive summary xii

1. Use of *Mycobacterium tuberculosis* antigen-based skin tests for the diagnosis of TB infection NEW 1

1.1. Background 1

1.2. Recommendation 3

1.3. Test descriptions 4

1.4. Evidence base 4

1.5. Implementation considerations 22

1.6. Monitoring and evaluation 22

1.7. Research priorities 22

2. Use of the TST and IGRAs for the diagnosis of TB infection 23

2.1. Background 23

2.2. Recommendation 23

2.3. Test descriptions 24

2.4. Evidence base 25

2.5. Implementation considerations 25

2.6. Research priorities 26

3. Use of the TST and IGRAs for the diagnosis of TB disease 27

3.1. Background 27

3.2. Recommendation 28

3.3. Test descriptions 28

3.4. Evidence base 28

3.5. Research priorities 33

References 35

Annex 1. Summary of changes between the 2011–2020 guidance and the 2022 update 37

Annex 2. GDG processes and decision-making 39

Annex 3. Conflict of interest assessment for Guideline Development Group and External Review Group members 40

Web annexes

Web Annex A. Accuracy of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis

Web Annex B. Safety of Mycobacterium tuberculosis antigen-based skin tests: a systematic review and meta-analysis

Web Annex C. GRADE profiles of Mycobacterium tuberculosis antigen-based skin tests

Web Annex D. Cost–effectiveness of Mycobacterium tuberculosis antigen-based skin tests: a systematic review

Web Annex E. Modelling for economic evidence for the use of Mycobacterium tuberculosis antigen-based skin tests

Web Annex F. Qualitative evidence for the use of Mycobacterium tuberculosis antigen-based skin tests

Web Annex G. Mycobacterium tuberculosis antigen-based skin tests: evidence-to-decision table

Web Annex H. Use of tuberculin skin test or interferon gamma release assays for identifying individuals at greatest risk of progression to active TB

Web Annex I. Diagnostic accuracy of interferon gamma release assays for evaluation of patients with pulmonary TB

Acknowledgements

The recommendations included in these consolidated policy guidelines on tuberculosis (TB) are the result of a collaborative effort among professionals from a range of specialities. The World Health Organization (WHO) is grateful for their time and support.

TB antigen-based skin tests (TBSTs) for the diagnosis of TB infection

GDG meeting on use of TBSTs for the diagnosis of TB infection, Geneva, Switzerland, 31 January–3 February 2022.

Guideline Development Group

Helen Ayles, London School of Hygiene & Tropical Medicine (LSHTM)/Zambart, United Kingdom of Great Britain and Northern Ireland (United Kingdom); **David Branigan**, Treatment Action Group, New York, United States of America (USA); **Jeremiah Chakaya Muhwa**, Co-chair, International Union Against Tuberculosis and Lung Disease, Nairobi, Kenya; **Daniela Cirillo**, San Raffaele Tuberculosis Supranational Reference Laboratory (SRL), Milan, Italy; **Frank Cobelens**, Amsterdam Institute of Global Health and Development, Netherlands; **Anand Date**, Centers for Disease Control and Prevention (CDC), Atlanta, USA; **Petra de Haas**, KNCV Tuberculosis Foundation, The Hague, Netherlands; **Rumina Hasan**, Department of Pathology and Microbiology, Aga Khan University, SRL Karachi, Pakistan; **Farzana Ismail**, Centre for Tuberculosis, National Institute for Communicable Diseases/National Health Laboratory Service and WHO SRL, Johannesburg, South Africa; **Katharina Kranzer**, LSHTM, Harare, Zimbabwe; **Afranio Kritski**, University of Rio de Janeiro, Brazil; **Blessina Kumar**, Global Coalition of TB Activists, India; **Nagalineswaran Kumarasamy**, Voluntary Health Services Infectious Diseases Medical Centre (VHS IDMC), Chennai, India; **Andrei Maryandyshev**, Nordic University, Arkhangelsk, Russian Federation; **Alberto Matteelli**, University of Brescia, Italy; **Satoshi Mitarai**, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (RIT/JATA), Japan; **Lindiwe Mvusi**, national TB programme (NTP), Pretoria, South Africa; **Mark Nicol**, University of Western Australia, Perth, Australia; **Leen Rigouts**, Prince Leopold Institute of Tropical Medicine, Brussels, Belgium; **Thomas Shinnick**, Independent Consultant, Atlanta, USA; **Hojoon Sohn**, Seoul National University College of Medicine, Seoul, Republic of Korea; **Sabira Tahseen**, NTP, Ministry of National Health Services Regulations and Coordination, Government of Pakistan, Islamabad, Pakistan; **Ezio Távora dos Santos Filho**, Civil Society Task Force Member, Rio de Janeiro, Brazil; **Carrie Tudor**, TB Project Director, International Council of Nurses, Durban, South Africa; **Marieke van der Werf**, European Centre for Disease Prevention and Control, Sweden; and **Yanlin Zhao**, National Center for Tuberculosis Control and Prevention, China CDC, Beijing, China.

Methodologist

Lawrence Mbuagbaw, McMaster University, Canada.

External Review Group

Francis Drobniewski, Imperial College London, United Kingdom; **Sergei Skornyakov**, Ural Research Institute for Phthisiopulmonology, National Medical Research Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of Russian Federation, Yekaterinburg, Russian Federation; **Francis Varaine**, Médecins Sans Frontières, Paris, France; and **Elisabetta Walters**, Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, South Africa.

Systematic review team

Molebogeng (Lele) Rangaka, University College London, United Kingdom; **Yohhei Hamada**, University College London, United Kingdom; **Lara Goscé**, University College London, United Kingdom; **Amy Chan**, University of Auckland, New Zealand; **Victoria Liu**, LSHTM, United Kingdom; **Ting Ting Wang**, University College London, United Kingdom; and **Liliya Ziganshina**, Cochrane Russia, Russian Federation.

Observers

Draurio Cravo Neto Barreira, Unitaid, Switzerland; **Fatim Cham-Jallow**, Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland; **Brian Kaiser**, Global Drug Facility, Stop TB Partnership, Switzerland; **Amy Piatek**, United States Agency for International Development (USAID), USA; **Morten Ruhwald**, Foundation for Innovative New Diagnostics (FIND), Switzerland; and **Wayne Van Gemert**, TB Diagnostics Market Strategies, Stop TB Partnership, Switzerland.

WHO steering committee

Work on these guidelines was overseen by **Nazir Ismail** and **Alexei Korobitsyn**, with input from **Dennis Falzon**, **Avinash Kanchar**, **Linh Nguyen**, **Lice Gonzalez-Angulo**, **Annabel Baddeley**, **Carl-Michael Nathanson** (all WHO Global TB Programme [WHO/GTB]), **Mercedes Gonzalez** (Science division, Research for Health department (SCI/RFH) and **Soudeh Ehsani** (WHO Regional Office for Europe) under the overall coordination of **Matteo Zignol** (WHO/GTB) and the direction of **Teresa Kasaeva**, Director of WHO/GTB.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_31945